A phase I metabolic study of ALKS 3831 in healthy subjects

Trial Profile

A phase I metabolic study of ALKS 3831 in healthy subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Olanzapine/samidorphan (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 12 Oct 2016 New trial record
    • 04 Oct 2016 Results from this study are expected in the first half of 2017, according to an Alkermes plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top